Search Results - "Skowronski, Danuta"

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine by Skowronski, Danuta M, De Serres, Gaston, Vergnes, Jean-Noel, Wang, Xiang, Absalon, Judith, Koury, Kenneth, Gruber, William C

“…To the Editor: Polack et al. (Dec. 31) 1 report a vaccine efficacy of 94.8% against Covid-19 after two doses of the messenger RNA (mRNA) vaccine BNT162b2…”
Get full text

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses by Skowronski, Danuta M, Janjua, Naveed Z, De Serres, Gaston, Sabaiduc, Suzana, Eshaghi, Alireza, Dickinson, James A, Fonseca, Kevin, Winter, Anne-Luise, Gubbay, Jonathan B, Krajden, Mel, Petric, Martin, Charest, Hugues, Bastien, Nathalie, Kwindt, Trijntje L, Mahmud, Salaheddin M, Van Caeseele, Paul, Li, Yan

“…Influenza vaccine effectiveness (VE) is generally interpreted in the context of vaccine match/mismatch to circulating strains with evolutionary drift in the…”
Get full text

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study by Carazo, Sara, Skowronski, Danuta M, Brisson, Marc, Barkati, Sapha, Sauvageau, Chantal, Brousseau, Nicholas, Gilca, Rodica, Fafard, Judith, Talbot, Denis, Ouakki, Manale, Gilca, Vladimir, Carignan, Alex, Deceuninck, Geneviève, De Wals, Philippe, De Serres, Gaston

“…There is a paucity of data on vaccine-induced or infection-induced (hybrid or natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in…”
Get full text

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence by Belongia, Edward A, Skowronski, Danuta M, McLean, Huong Q, Chambers, Catharine, Sundaram, Maria E, De Serres, Gaston

“…Studies in the 1970s and 1980s signaled concern that repeated influenza vaccination could affect vaccine protection. The antigenic distance hypothesis provided…”
Get full text

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012-2013 Season by Skowronski, Danuta M, De Serres, Gaston

Get full text

Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada by Skowronski, Danuta M, Kaweski, Samantha E, Irvine, Michael A, Kim, Shinhye, Chuang, Erica S Y, Sabaiduc, Suzana, Fraser, Mieke, Reyes, Romina C, Henry, Bonnie, Levett, Paul N, Petric, Martin, Krajden, Mel, Sekirov, Inna

“…The evolving proportion of the population considered immunologically naive versus primed for more efficient immune memory response to SARS-CoV-2 has…”
Get full text

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada by Skowronski, Danuta M, De Serres, Gaston, Crowcroft, Natasha S, Janjua, Naveed Z, Boulianne, Nicole, Hottes, Travis S, Rosella, Laura C, Dickinson, James A, Gilca, Rodica, Sethi, Pam, Ouhoummane, Najwa, Willison, Donald J, Rouleau, Isabelle, Petric, Martin, Fonseca, Kevin, Drews, Steven J, Rebbapragada, Anuradha, Charest, Hugues, Hamelin, Marie-Eve, Boivin, Guy, Gardy, Jennifer L, Li, Yan, Kwindt, Trijntje L, Patrick, David M, Brunham, Robert C

“…In late spring 2009, concern was raised in Canada that prior vaccination with the 2008-09 trivalent inactivated influenza vaccine (TIV) was associated with…”
Get full text

Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008–2009 Seasonal Influenza Vaccine Receipt by Skowronski, Danuta M, De Serres, Gaston

Get full text

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement by De Serres, Gaston, Skowronski, Danuta M, Ward, Brian J, Gardam, Michael, Lemieux, Camille, Yassi, Annalee, Patrick, David M, Krajden, Mel, Loeb, Mark, Collignon, Peter, Carrat, Fabrice

“…Four cluster randomized controlled trials (cRCTs) conducted in long-term care facilities (LTCFs) have reported reductions in patient risk through increased…”
Get full text

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season by Skowronski, Danuta M., Chambers, Catharine, Sabaiduc, Suzana, De Serres, Gaston, Winter, Anne-Luise, Dickinson, James A., Krajden, Mel, Gubbay, Jonathan B., Drews, Steven J., Martineau, Christine, Eshaghi, Alireza, Kwindt, Trijntje L., Bastien, Nathalie, Li, Yan

“…Background. The 2014–2015 influenza season was distinguished by an epidemic of antigenically-drifted A(H3N2) viruses and vaccine components identical to…”
Get full text

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010–2011 to 2014–2015 by Skowronski, Danuta M., Chambers, Catharine, De Serres, Gaston, Sabaiduc, Suzana, Winter, Anne-Luise, Dickinson, James A., Gubbay, Jonathan B., Fonseca, Kevin, Drews, Steven J., Charest, Hugues, Martineau, Christine, Krajden, Mel, Petric, Martin, Bastien, Nathalie, Li, Yan, Smith, Derek J.

“…Background. The antigenic distance hypothesis (ADH) predicts that negative interference from prior season's influenza vaccine (v1) on the current season's…”
Get full text

Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023 by Razafimandimby, Harimahefa, Sauvageau, Chantal, Ouakki, Manale, Carazo, Sara, Skowronski, Danuta M, De Serres, Gaston

“…In premarketing clinical trials conducted before Omicron emergence, BNT162b2 vaccine efficacy against COVID-19 was 90% in children. We conducted postmarketing…”
Get full text

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada by Skowronski, Danuta M, Febriani, Yossi, Ouakki, Manale, Setayeshgar, Solmaz, El Adam, Shiraz, Zou, Macy, Talbot, Denis, Prystajecky, Natalie, Tyson, John R, Gilca, Rodica, Brousseau, Nicholas, Deceuninck, Geneviève, Galanis, Eleni, Fjell, Chris D, Sbihi, Hind, Fortin, Elise, Barkati, Sapha, Sauvageau, Chantal, Naus, Monika, Patrick, David M, Henry, Bonnie, Hoang, Linda M N, De Wals, Philippe, Garenc, Christophe, Carignan, Alex, Drolet, Mélanie, Jassem, Agatha N, Sadarangani, Manish, Brisson, Marc, Krajden, Mel, De Serres, Gaston

“…The Canadian coronavirus disease 2019 (COVID-19) immunization strategy deferred second doses and allowed mixed schedules. We compared 2-dose vaccine…”
Get full text

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration by Ionescu, Iulia G, Skowronski, Danuta M, Sauvageau, Chantal, Chuang, Erica, Ouakki, Manale, Kim, Shinhye, De Serres, Gaston

“…Abstract Background Two- and 3-dose BNT162b2 vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,…”
Get full text

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada by Skowronski, Danuta M, Setayeshgar, Solmaz, Zou, Macy, Prystajecky, Natalie, Tyson, John R, Galanis, Eleni, Naus, Monika, Patrick, David M, Sbihi, Hind, El Adam, Shiraz, Henry, Bonnie, Hoang, Linda M N, Sadarangani, Manish, Jassem, Agatha N, Krajden, Mel

“…Abstract Background Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2…”
Get full text

Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012–2013 to 2018–2019 Seasons, Quebec, Canada by Carazo, Sara, Guay, Charles-Antoine, Skowronski, Danuta M, Amini, Rachid, Charest, Hugues, De Serres, Gaston, Gilca, Rodica

“…Abstract Background Influenza immunization programs aim to reduce the risk and burden of severe outcomes. To inform optimal program strategies, we monitored…”
Get full text

Serial cross-sectional estimation of vaccineand infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada by Skowronski, Danuta M, Kaweski, Samantha E, Irvine, Michael A, Kim, Shinhye, Chuang, Erica S Y, Sabaiduc, Suzana, Fraser, Mieke, Reyes, Romina C, Henry, Bonnie, Levett, Paul N, Petric, Martin, Krajden, Mel, Sekirov, Inna

“…Background: The evolving proportion of the population considered immunologically naive versus primed for more efficient immune memory response to SARS-CoV-2…”
Get full text

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits by De Serres, Gaston, Skowronski, Danuta M

Get full text

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation by Skowronski, Danuta M, De Serres, Gaston, Orenstein, Walter A

Get full text

Pooling and the Potential Dilution of Repeat Influenza Vaccination Effects by Skowronski, Danuta M., Chambers, Catharine

Get full text